The VaSecure BTK Study

This is an interventional treatment trial for Peripheral Artery Disease Read More

Inclusion Criteria:

1. Able to provide written informed consent prior to participating in the clinical investigation, e.g. patients are mentally able to understand the aim of the clinical investigation.
2. Has a documented diagnosis of CLTI of Rutherford category 3-5.
3. The target lesion must be de novo.
4. Life expectancy is >1 year, in the investigator's opinion.
5. For women: menopausal or under active birth control.

6. Patient must agree not to participate in any other clinical trial during 12 month follow-up period.

   Visual angiographic inclusion criteria

7. Reference vessel(s) diameter is between 2mm-4mm. Each lesion in one or maximum two of the infrapopliteal arteries NOT extending beyond the ankle joint. Target lesion(s) consisting of a single solitary or series of multiple adjacent lesions (all less than 30 mm apart) in a single tibial vessel with a diameter stenosis ≥70% and a cumulative length of ≥50 mm to ≤250 mm. If there are two target lesions they will be separated for ≥3 cm and will be named from proximal to distal. Target lesion must be a tibial vessel (excluding popliteal artery) branching from popliteal artery.

Exclusion Criteria:

1. Breastfeeding or pregnant woman.
2. Severe concentric calcification, documented by angiography using the COMPLIANCE360-Score (This scoring system takes into account both the arc of calcium (< or > 180º) and percent of lesion length (< or > 50%) as judged by fluoroscopy.) that could not be fully expanded by predilatation balloon and documented by angiography. Valid record up to 30 days before screening.
3. Patients with major amputations that have already been performed or are planned, either on the target leg or on the contralateral side. .
4. History of stroke within 3 months.
5. History of myocardial infarction, thrombolysis or angina within 30 days prior to index procedure.
6. Renal failure or chronic kidney disease with estimated Glomerular Filtration Rate (eGFR) ≤30 mL/min per 1.73 m2 (or serum creatinine ≥2.5 mg/dL within 30 days of index procedure or treated with dialysis).
7. Diagnosed active untreated systemic infection or uncontrolled coagulopathy within 14 days prior to index procedure.
8. Co-morbid conditions limiting life expectancy to <12 months.
9. Hemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy.
10. Known allergy to paclitaxel or paclitaxel-related compounds or contrast media that cannot be adequately managed with pre- and post-procedure medication.
11. Is currently participating in an investigational drug or other investigational device study or previously enrolled in this study.
12. Is unlikely to comply with the follow up schedule.
13. Has uncontrolled ulcer wound infection.
14. Is unwilling to comply with a concurrent ulcer wound therapy.
15. Has an allergy to acetylsalicylic acid, prasugrel, ticagrelol, and clopidogrel (Plavix®).

16. Use of atherectomy in proximal vessels or TL. However, the use of scoring/cutting balloons in the TL is allowed.

    Angiographic exclusion criteria

17. Lesions that cannot be successfully predilated to achieve a residual stenosis of <50% by visual estimate.
18. Severe dissection post dilatation resulting in a flow limiting lesion.
19. Thrombus in the target vessel documented by angiography.
20. Aneurysm in the target vessel(s).
21. Treatment of the contralateral limb during the same index procedure or within 30 days post-index procedure in order to avoid confounding complications.